Novartis AG

NOVNSwitzerlandAlso United States · NVS

39 filed reports · 857 financial concepts · 42 earnings calls · 22 media appearances

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Net income

$14B

FY2025 · to Dec 31, 2025

up +17.0% vs $11.9B

20-F

Operating income

$17.6B

FY2025 · to Dec 31, 2025

up +21.3% vs $14.5B

20-F

Latest quarter

Net income

$1.2B

Q3 FY2026 · to Sep 30, 2026

Q3 report

Operating income

$4.75B

Q2 FY2026 · to Jun 30, 2026

down −2.3% vs $4.86B

6-K

Filed reports

39 reports · Apr 2009 to Nov 2026

Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 26 guidance figures, 700 interim figures.

Report typeReportsFactsPeriods
Q3SIX-listed company reports2200Sep 2025 to Sep 2026
AnnualSIX-listed company reports195Dec 2025
Half YearSIX-listed company reports1128Jun 2026
Q1SIX-listed company reports188Mar 2026
Interim · 6-KSEC EDGAR254,832Apr 2009 to Nov 2026
Annual · 20-FSEC EDGAR75,123Dec 2018 to Dec 2025
Annual · 20-F/ASEC EDGAR2861Dec 2021 to Dec 2022

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q36-K2026-11-192026-11-193Open
FY2026 Q36-K2026-09-302026-10-274Open
FY2026 Q3q32026-09-302026-09-30188Open
FY2026 Q36-K2026-09-082026-09-082Open
FY2026 Q26-K2026-06-302026-07-21655Open
FY2026 Q2half year2026-06-302026-06-30128Open
FY2026 Q1q12026-03-312026-03-3188Open
FY202520-F2025-12-312026-02-041,211Open
FY2025annual2025-12-312025-12-3195Open
FY2025 Q3q32025-09-302025-10-2812Open
FY2025 Q26-K2025-06-302025-07-17314Open
FY202420-F2024-12-312025-01-31546Open

Financial data

857 concepts · 11,327 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial632 concepts · 8,531 facts · Dec 2015 to Jun 2026

  • Innovative Medicines92 · Dec 2016 to Jun 2026
  • Operating segments [member]68 · Dec 2016 to Dec 2025
  • Total treasury shares68 · Dec 2015 to Dec 2025
  • Purchase of treasury shares42 · Dec 2015 to Jun 2026
  • Long-term financial debt with a carrying amount40 · Dec 2017 to Jun 2026
  • Switzerland40 · Dec 2016 to Dec 2025
  • Operating segments [member]39 · Dec 2015 to Dec 2025
  • Property, plant and equipment36 · Dec 2017 to Dec 2025
  • Cash and cash equivalents34 · Dec 2015 to Jun 2026
  • Equity34 · Dec 2015 to Jun 2026
  • Deferred tax assets33 · Dec 2016 to Jun 2026
  • Noncontrolling interests33 · Dec 2016 to Jun 2026
  • Retained earnings33 · Dec 2017 to Jun 2026
  • Not later than one year32 · Dec 2016 to Dec 2025
  • Stockholders Equity32 · Dec 2016 to Jun 2026
  • Adjustments for reconcile profit loss31 · Dec 2015 to Jun 2026
  • Cash flows from used in financing activities31 · Dec 2015 to Jun 2026
  • Cash flows from used in increase decrease in current borrowings31 · Dec 2015 to Jun 2026
  • Cash flows from used in investing activities31 · Dec 2015 to Jun 2026
  • Changes in equity31 · Dec 2015 to Jun 2026
  • Comprehensive income31 · Dec 2015 to Jun 2026
  • Comprehensive income attributable to noncontrolling interests (IFRS)31 · Dec 2015 to Jun 2026
  • Comprehensive income attributable to owners of parent (IFRS)31 · Dec 2015 to Jun 2026
  • Cost of sales31 · Dec 2015 to Jun 2026

Segment39 concepts · 1,752 facts · Dec 2015 to Jun 2023

  • Operating segments [member]328 · Dec 2015 to Jun 2023
  • Innovative Medicines141 · Dec 2016 to Jun 2023
  • Cost of sales74 · Dec 2015 to Jun 2023
  • Gross profit (IFRS)74 · Dec 2015 to Jun 2023
  • Other expense by function74 · Dec 2015 to Jun 2023
  • Other income (IFRS)74 · Dec 2015 to Jun 2023
  • Profit loss from operating activities74 · Dec 2015 to Jun 2023
  • Revenue from sale of goods (IFRS)74 · Dec 2015 to Jun 2023
  • Other revenue (IFRS)71 · Dec 2015 to Jun 2023
  • Selling general and administrative expense (IFRS)70 · Dec 2016 to Jun 2023
  • Switzerland70 · Jun 2019 to Jun 2023
  • Revenue from royalties65 · Dec 2016 to Jun 2023
  • Property, Plant & Equipment, Net63 · Dec 2016 to Jun 2023
  • Share of profit loss of associates and joint ventures accounted for using equity method58 · Dec 2015 to Jun 2023
  • Research and development expense (IFRS)53 · Dec 2015 to Jun 2023
  • Total Assets52 · Dec 2016 to Jun 2023
  • Intangible Assets (excluding Goodwill)39 · Dec 2017 to Jun 2023
  • Goodwill37 · Dec 2017 to Jun 2023
  • Total Liabilities33 · Dec 2017 to Jun 2023
  • Additions other than through business combinations intangible assets other than goodwill24 · Dec 2016 to Dec 2022
  • Additions other than through business combinations property plant and equipment24 · Dec 2016 to Dec 2022
  • Cost of Revenue23 · Jun 2017 to Jun 2023
  • Operating Income23 · Jun 2017 to Jun 2023
  • Gross Profit20 · Jun 2017 to Jun 2023

Geography8 concepts · 498 facts · Dec 2015 to Dec 2026

  • Operating segments [member]147 · Dec 2015 to Jun 2023
  • Switzerland121 · Dec 2015 to Dec 2026
  • Revenue from sale of goods (IFRS)116 · Dec 2021 to Jun 2026
  • US57 · Dec 2021 to Jun 2026
  • Profit loss before tax20 · Dec 2015 to Dec 2025
  • Current tax expense income18 · Dec 2016 to Dec 2025
  • Deferred tax expense income18 · Dec 2016 to Dec 2025
  • France1 · Dec 2025

IFRS160 concepts · 488 facts · Dec 2025 to Sep 2026

  • Non-controlling interests11 · Dec 2025 to Sep 2026
  • Property, Plant & Equipment, Net7 · Dec 2025 to Sep 2026
  • Total7 · Mar 2026 to Sep 2026
  • EPS (Basic)6 · Dec 2025 to Sep 2026
  • EPS (Diluted)6 · Dec 2025 to Sep 2026
  • Intangible Assets (excluding Goodwill)6 · Dec 2025 to Sep 2026
  • Loss from associated companies6 · Dec 2025 to Sep 2026
  • Other financial income and expense6 · Dec 2025 to Sep 2026
  • Right-of-Use Assets6 · Dec 2025 to Sep 2026
  • Cash and Equivalents5 · Dec 2025 to Sep 2026
  • Cash flow hedge, net of taxes5 · Mar 2026 to Sep 2026
  • Change in current financial debts5 · Dec 2025 to Sep 2026
  • Currency translation effects, net of taxes5 · Mar 2026 to Sep 2026
  • Divestments of businesses, net5 · Dec 2025 to Sep 2026
  • Fair value adjustments on equity securities, net of taxes5 · Mar 2026 to Sep 2026
  • Income Tax Expense (Benefit)5 · Dec 2025 to Sep 2026
  • Interest paid5 · Dec 2025 to Sep 2026
  • Interest received5 · Dec 2025 to Sep 2026
  • Investments in time deposits and marketable securities5 · Dec 2025 to Sep 2026
  • Net investment hedge, net of taxes5 · Mar 2026 to Sep 2026
  • Other financing cash flows, net5 · Dec 2025 to Sep 2026
  • Other investing cash flows, net5 · Dec 2025 to Sep 2026
  • Payments of lease liabilities5 · Dec 2025 to Sep 2026
  • Proceeds from sale of financial assets5 · Dec 2025 to Sep 2026

Guidance5 concepts · 35 facts · Apr 2009 to Nov 2026

  • Revenue Growth Guidance26 · Apr 2009 to Oct 2026
  • Revenue Growth Guidance (Constant currency)4 · Oct 2026 to Nov 2026
  • Operating Income Guidance2 · Jul 2011
  • Revenue Guidance2 · Jul 2011
  • Operating Margin Guidance (Adjusted (non-GAAP))1 · Nov 2026

APM6 concepts · 13 facts · Sep 2025 to Sep 2026

  • Net debt3 · Mar 2026 to Sep 2026
  • As a % of sales2 · Sep 2025
  • Core EPS (USD)2 · Sep 2025
  • Core net income2 · Sep 2025
  • Core operating income2 · Sep 2025
  • Free cash flow2 · Sep 2025

KPI7 concepts · 10 facts · Sep 2025 to Sep 2026

  • Liquidity3 · Mar 2026 to Sep 2026
  • As a % of sales2 · Sep 2025
  • Average interest rate during the year1 · Dec 2025
  • Average interest rate on total financial debts1 · Dec 2025
  • listed equity securities1 · Dec 2025
  • non-listed equity securities1 · Dec 2025
  • Percentage of fixed-rate financial debts to total financial debts1 · Dec 2025

Segments

2,250 facts

Figures broken down by business line, region, product or another axis the company reports on.

Segments9 members · 1,752 facts

  • Innovative Medicines547 · Dec 2015 to Jun 2023
  • Sandoz504 · Dec 2015 to Jun 2023
  • Corporate282 · Dec 2015 to Jun 2023
  • Alcon112 · Dec 2015 to Jun 2021
  • Innovative medicines98 · Dec 2016 to Jun 2023
  • Sandoz95 · Dec 2016 to Jun 2023
  • Corporate88 · Dec 2016 to Jun 2023
  • Alcon25 · Dec 2016 to Dec 2018
  • Consumer Health1 · Dec 2017

Geographical areas16 members · 498 facts

  • Country Of Domicile67 · Dec 2015 to Dec 2026
  • US54 · Dec 2015 to Jun 2026
  • Asia Africa Australasia42 · Dec 2018 to Jun 2026
  • Europe42 · Dec 2018 to Jun 2026
  • Canada And Latin America37 · Dec 2018 to Jun 2026
  • Emerging Growth Markets37 · Dec 2018 to Jun 2026
  • Established Markets37 · Dec 2018 to Jun 2026
  • Foreign Countries34 · Dec 2015 to Dec 2025
  • DE26 · Dec 2015 to Dec 2025
  • Other Countries26 · Dec 2015 to Dec 2025
  • FR25 · Dec 2015 to Dec 2025
  • JP22 · Dec 2015 to Dec 2023
  • CN20 · Dec 2018 to Dec 2025
  • Rest Of The World11 · Dec 2021 to Jun 2026
  • Americas10 · Dec 2018 to Dec 2022
  • GB8 · Dec 2015 to Dec 2018

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

  • Management discussion (MD&A) commentary43 claims from 2 reports · Dec 2024 to Dec 2025
  • Risk-factor changes88 claims from 7 reports · Dec 2019 to Dec 2025
  • Risk factors207 risks from 8 annual reports · 2018 to 2025

Earnings calls

42 calls · Jul 2016 to Oct 2026

Transcripts with management claims and analyst questions, one per fiscal period.

  • FY2026 Q32026-10-27
  • FY2026 Q22026-07-21
  • FY2026 Q12026-04-28
  • FY2025 Q42026-02-04
  • FY2025 Q32025-10-28
  • FY2025 Q22025-07-17
  • FY2025 Q12025-04-29
  • FY2024 Q42025-01-31
  • FY2024 Q32024-10-29
  • FY2024 Q22024-07-18
  • FY2024 Q12024-04-23
  • FY2023 Q42024-01-31
  • FY2023 Q32023-10-24
  • FY2023 Q22023-07-18
  • FY2023 Q12023-04-25
  • FY2022 Q42023-02-01

Executive media

22 appearances

Podcasts, interviews and conference appearances by the company's executives, with their claims.

  • TV interviews17 · Jan 2020 to Jul 2026
  • Podcasts3 · Mar 2024 to Jun 2025
  • Other appearances2 · Nov 2022 to Jul 2026

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of Novartis AG (NOVN) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.

Novartis AG (NOVN): FY2025 net income $14B · FactIQ